FBT Among Technology ETFs
End-of-day Nov 16, 2026 · 58 Technology ETFs by Max
| Returns | Today | 1W | 1M | 3M | YTD | 1Y | 3Y | 5Y | Max |
|---|---|---|---|---|---|---|---|---|---|
| Total return | −1.5% | −2.4% | +1.3% | +2.4% | +29.3% | +33.7% | +98.5% | +63.9% | +1,025.0% |
| Peer average | −2.9% | −3.9% | −7.3% | −10.9% | +3.1% | +4.6% | +69.6% | +21.7% | — |
| S&P 500 · VOO | −1.9% | −1.7% | −3.0% | −3.3% | +9.4% | +11.3% | +77.3% | +69.2% | — |
$45 of every $1,000 in FBT is Genmab
| # | ||||||
|---|---|---|---|---|---|---|
| 1 | GMABGenmab A/S () | Healthcare | 4.52% | $452.39 | 2.7M | $140.0M |
| 2 | ADMAADMA Biologics | Healthcare | 4.31% | $431.07 | 9.8M | $133.4M |
| 3 | REGNRegeneron Pharmaceuticals | Healthcare | 4.18% | $417.81 | 135K | $129.3M |
| 4 | NBIXNeurocrine Biosciences | Healthcare | 3.84% | $383.66 | 709K | $118.7M |
| 5 | ONCBeOne Medicines () | Healthcare | 3.84% | $383.62 | 285K | $118.7M |
| 6 | TGTXTG Therapeutics | Healthcare | 3.80% | $380.34 | 1.8M | $117.7M |
| 7 | ARGXargenx SE () | Healthcare | 3.80% | $379.88 | 122K | $117.5M |
| 8 | ALKSAlkermes | Healthcare | 3.78% | $378.06 | 2.5M | $117.0M |
| 9 | EXELExelixis | Healthcare | 3.76% | $376.30 | 1.7M | $116.4M |
| 10 | BIIBBiogen | Healthcare | 3.67% | $366.50 | 448K | $113.4M |
| 11 | AMGNAmgen | Healthcare | 3.66% | $366.43 | 243K | $113.4M |
| 12 | GILDGilead Sciences | Healthcare | 3.63% | $362.97 | 668K | $112.3M |
| 13 | TARSTarsus Pharmaceuticals | Healthcare | 3.58% | $358.23 | 1.4M | $110.8M |
| 14 | UTHRUnited Therapeutics | Healthcare | 3.51% | $351.43 | 184K | $108.7M |
| 15 | INCYIncyte | Healthcare | 3.50% | $350.13 | 896K | $108.3M |
of the $354B in 58 Technology ETFs
| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S () | 4.52% |
| 2 | ADMA | ADMA Biologics | 4.31% |
| 3 | REGN | Regeneron Pharmaceuticals | 4.18% |
| 4 | NBIX | Neurocrine Biosciences | 3.84% |
| 5 | ONC | BeOne Medicines () | 3.84% |
| 6 | TGTX | TG Therapeutics | 3.80% |
| 7 | ARGX | argenx SE () | 3.80% |
| 8 | ALKS | Alkermes | 3.78% |
| 9 | EXEL | Exelixis | 3.76% |
| 10 | BIIB | Biogen | 3.67% |
Estimated yearly cost excludes trading costs and assumes constant assets.
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 13, 2024 | Dec 31, 2024 | $1.17 |
| Dec 30, 2021 | Jan 10, 2022 | $2.21 |
| Sep 23, 2015 | Sep 30, 2015 | $0.0200 |
| Jun 24, 2015 | Jun 30, 2015 | $0.0650 |
| Mar 25, 2015 | Mar 31, 2015 | $0.0480 |
| Dec 23, 2014 | Dec 31, 2014 | $0.0524 |
| Jun 23, 2008 | Jun 30, 2008 | $0.27 |